Saint Luke's Mid America Heart Institute
@MidAmericaHeart
Followers
2K
Following
1K
Media
222
Statuses
825
Twitter home of Mid America Heart Institute, St. Luke’s Hospital of Kansas City @saintlukeskc https://t.co/Hcb1gGpaOJ
Kansas City, MO
Joined October 2018
Fellowship application season is upon us! @UMKC and Saint Luke's @MidAmericaHeart offers: ✴️ 3 yr CV fellowship ✴️ 4 yr T32 clinical/research track ✴️ Advanced HF ✴️ EP ✴️ Interventional ✴️ Structural ✴️ CV Imaging ✴️ Prevention Apply today! https://t.co/7V9IO7eicX
2
8
39
Apply for Structural Intervention fellowship here! Excellent opportunity to train at a high volume program.
The Cardiovascular Structural Intervention Fellowship through @UMKCMedSchool and @MidAmericaheart accepts one candidate per academic year. Fellows benefit from getting hands-on training from renowned specialists. Learn more and request an application now: https://t.co/ZhEIgzthee
0
5
19
The Cardiovascular Structural Intervention Fellowship through @UMKCMedSchool and @MidAmericaheart accepts one candidate per academic year. Fellows benefit from getting hands-on training from renowned specialists. Learn more and request an application now: https://t.co/ZhEIgzthee
0
6
14
Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025. BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: https://t.co/wpXdGLElw2
3
0
3
Star fellow @mirzakhan_ presenting data on geographic patterns of prescriptions for amyloid medications from EPIC Cosmos at #ACC25
@MidAmericaHeart
1
3
22
Understanding patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM) is vital for managing treatment effectively. We recently validated the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) in this population. Here’s why it matters: A quick🧵
2
17
37
At #ESCHF2025 🇷🇸 @MidAmericaHeart fellow Dr Omar Cantu-Martinez presents #CAREHKinHF real-world registry: >2,300 HF pts w/ hyperK risk with 9% on clinician selected patiromer. Reduced severe HK and trend toward more optimal GDMT. Take-home: early K⁺ control keeps GDMT on &
3
4
34
Grateful for the opportunity to work with @Amgen in collaboration with @cardiometalli @MidAmericaHeart as part of the LATTICE Consortium to address implementation of cardiometabolic therapies and stepping into the gaps.
LATTICE™ isn’t just talking progress in cardiovascular care—it’s helping define it. Catch highlights from the LATTICE™ #NLASessions presentation and hear from experts @AndrewJSauer, @Nishant_ShahMD & @LaneyJonesRx on what’s driving change: https://t.co/ytKvxGaJuQ
0
2
13
Special focus issue in @JACCJournals this week on Cardiac Amyloidosis. Many important articles! Sharing my editorial with Joban Vaishnav from @JohnsHopkins
https://t.co/Q2EBUABhw0
1
23
63
One of the defining aspects of our fellowship are our accomplished alumni. As a part of our fellowship research day, Dr. Chhatriwalla honored us with a noon conference on advancements in ViV TAVR and bioprosthetic valve fracture! @akcmahi @venumenon10
3
5
30
Art Still, a former @Chiefs defensive end, has dedicated himself to increasing awareness for ATTR amyloidosis ever since his diagnosis in 2023. @TODAYshow spoke with Dr. Brett Sperry, a @MidAmericaHeart cardiologist, to discuss the rare genetic condition:
today.com
Art Still has ATTR amyloidosis, an inherited heart condition that dramatically impacts Black men and the former Kansas City Chiefs defensive end wants to raise awareness.
0
0
2
Outside of her work as an oncologist, Dr. Juliet Appiah helps cancer patients in her home country of Ghana. Dr. Appiah spoke with @KSHB41 about her passion for giving back to her home country and raising awareness for all types of cancer. Watch now: https://t.co/GSMeSI9bm3
0
0
2
Here are some reasons why you should train with us in Cardiovascular Disease at the University of Missouri-Kansas City School of Medicine program @MidAmericaHeart @saintlukeskc!
1
6
15
Proof I made it to @escardio Let’s go! Check out @JACCJournals publications our team is releasing soon during London sessions. https://t.co/stkJGQKK1x
@MkosiborodMD
@jspertus
@MidAmericaHeart
@saintlukeskc
0
4
46
Semaglutide and obesity related HFpEF Patients with atrial fibrillation and obesity HFpEF are generally more burdened/congested at baseline and also may benefit more from GLP1 in health status and walking distance. @MkosiborodMD
@MidAmericaHeart
https://t.co/Pd16sJe54A
0
3
3
Inflammation reduction by semaglutide as measured by CRP tracks with magnitude of NTproBNP reduction.
0
2
1
Semaglutide and obesity HFpEF Echo markers Improved LA volume reduction and markers of diastolic function with GLP1 compared to placebo. @mvaduganathan
@BiykemB
@MkosiborodMD
2
20
63
CV outcomes from FLOW trial. Semaglutide vs placebo focused on patients with HF within larger population of T2DM and CKD.
1
3
14
Pooled analysis of patients with HFpEF in STEP-HFpEF, SELECT, and FLOW @MkosiborodMD
@MidAmericaHeart
@saintlukeskc
@mvaduganathan
1
16
54
Here are some reasons why you should train with us in Cardiovascular Disease at the University of Missouri-Kansas City School of Medicine program @MidAmericaHeart @saintlukeskc!
1
6
15
Excited to be joining Saint Luke’s Mid America Heart Institute in Kansas City to help care for ACHD patients at the only accredited program in the Missouri/Kansas area @MidAmericaHeart @ACHA_Heart
Congratulations to the Kansas City Adult Congenital Heart Disease Program on becoming ACHA #ACHD Accredited! There are currently 53 accredited centers in a total of 28 states and Washington, D.C. Learn more about our accreditation program at https://t.co/ACOAKExAiY.
4
3
49